B

BioLine RX Ltd
NASDAQ:BLRX

Watchlist Manager
BioLine RX Ltd
NASDAQ:BLRX
Watchlist
Price: 2.8 USD 1.08% Market Closed
Market Cap: 223.8m USD

Net Margin
BioLine RX Ltd

-23.4%
Current
-159%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.4%
=
Net Income
-3m
/
Revenue
12.7m

Net Margin Across Competitors

No Stocks Found

BioLine RX Ltd
Glance View

Market Cap
223.8m USD
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
6.89 USD
Undervaluation 59%
Intrinsic Value
Price
B
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-23.4%
=
Net Income
-3m
/
Revenue
12.7m
What is the Net Margin of BioLine RX Ltd?

Based on BioLine RX Ltd's most recent financial statements, the company has Net Margin of -23.4%.

Back to Top